Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Group of Professor Kristijan Ramadan has published an original scientific article in Nature Communications today. The article has the first report of a new autophagy receptor TEX264, which may be involved in tumours developing drug resistance.

 

Autophagy (self-eating) is a critical cell process that allows cells to degrade and cycle damaged cell components.  In this case, TEX264 is key to identifying and recycling DNA with a permanent chemical link to a protein.

Covalent attachment of proteins to DNA is a constant problem.  Unless cells can clear their DNA of attached proteins they would die, so we knew they could do this, we just didn’t know how.

 Kristijan Ramadan’s group has uncovered how cells handle one example of this, the formation of a permanent link between DNA and a protein called Topoisomerase 1 to give a Topoisomerase 1 -cleavage complex (Top1-ccs).  Topoisomerase 1 (Top-1) is usually involved in unwinding DNA strands so that they may be easily copied, but if Top-1 gets permanently linked to DNA copying would get stuck and the cell would suffer further DNA damage. 

Specialised DNA repair machinery composed of the p97 ATPase, SPRTN protease and an autophagy receptor TEX264, tackles the linked protein-DNA.   Inactivation of the p97-SPRTN-TEX264 complex leads to accumulation of Top1-ccs and genomic instability. Pathological accumulation of Top1-ccs is linked to neurodegeneration and cancer.

The discovery of TEX264 and role it plays in resolving problems associated with covalent linking of proteins to DNA is important for cancer therapy, as Topoisomerase 1 inhibitors are one of the commonly used chemotherapeutics and they kill cancer cells by accumulation of Top1-ccs. Kristijan Ramadan’s report could be vital in treating tumours which have become resistant to Topoisomerase 1 inhibitors.

 

The full publication can be read here

Similar stories

Lung abnormalities found in long COVID patients with breathlessness

Researchers have identified abnormalities in the lungs of long COVID patients who are experiencing breathlessness that cannot be detected with routine tests.

New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread

A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.

Eileen Parkes secures Clinical Research Career Development Fellowship

Eileen is awarded funding for her research into the tumour microenvironment

MP Anneliese Dodds tours Oxford cancer research

Anneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the University of Oxford to learn more about the impactful work happening across departments in the field of cancer research.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.